drugset
drugset / Trial / NCT05951608

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

NCT05951608 ↗

Phase 1/2 Active not recruiting 216 enrolled Akeso
NaSingle-groupOpen-labelTreatment

Summary

A Phase Ib/II Open-label Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AK127 in combination with AK112 in Patients with Advanced Malignant Tumors

Timeline

Start
2023-10-16
Primary completion
2026-05-01
Completion
2026-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody — Intravenous
Subject LANCASTOTUG Monoclonal antibody — Intravenous

Indications

cancer